Emshoff V - Search Results

1

Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance.

Maenpaa J, Wiebe V, Wurz G, Koester S, Emshoff V, Seymour R, DeGregorio M. Maenpaa J, et al. Among authors: emshoff v. Cancer Chemother Pharmacol. 1994;35(2):149-52. doi: 10.1007/BF00686638. Cancer Chemother Pharmacol. 1994. PMID: 7987992

2

A breast cancer clone selected by tamoxifen has increased growth rate and reduced sensitivity to doxorubicin.

Maenpaa JU, Wurz GT, Baker WJ, Wiebe VJ, Emshoff VD, Koester SK, Seymour RC, Koehler RE, DeGregorio MW. Maenpaa JU, et al. Among authors: emshoff vd. Oncol Res. 1993;5(12):461-6. Oncol Res. 1993. PMID: 8086667

3

Prolonged tamoxifen exposure selects a breast cancer cell clone that is stable in vitro and in vivo.

Sipila PE, Wiebe VJ, Hubbard GB, Koester SK, Emshoff VD, Maenpaa JU, Wurz GT, Seymour RC, DeGregorio MW. Sipila PE, et al. Among authors: emshoff vd. Eur J Cancer. 1993;29A(15):2138-44. doi: 10.1016/0959-8049(93)90049-l. Eur J Cancer. 1993. PMID: 8297653

4

Targeting chemosensitizing doses of toremifene based on protein binding.

Wurz GT, Emshoff VD, DeGregorio MW, Wiebe VJ. Wurz GT, et al. Among authors: emshoff vd. Cancer Chemother Pharmacol. 1993;31(5):412-4. doi: 10.1007/BF00686157. Cancer Chemother Pharmacol. 1993. PMID: 8431976

5

A bioassay for antiestrogenic activity--potential utility in drug development and monitoring effective in vivo dosing.

DeGregorio M, Wurz G, Emshoff V, Koester S, Minor P, Wiebe V. DeGregorio M, et al. Among authors: emshoff v. Breast Cancer Res Treat. 1992;24(1):35-41. doi: 10.1007/BF01832356. Breast Cancer Res Treat. 1992. PMID: 1463870

6

Topical toremifene: a new approach for cutaneous melanoma?

Maenpaa J, Dooley T, Wurz G, VandeBerg J, Robinson E, Emshoff V, Sipila P, Wiebe V, Day C, DeGregorio M. Maenpaa J, et al. Among authors: emshoff v. Cancer Chemother Pharmacol. 1993;32(5):392-5. doi: 10.1007/BF00735925. Cancer Chemother Pharmacol. 1993. PMID: 8339391

7

Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer.

Maenpaa J, Wiebe V, Koester S, Wurz G, Emshoff V, Seymour R, Sipila P, DeGregorio M. Maenpaa J, et al. Among authors: emshoff v. Cancer Chemother Pharmacol. 1993;32(5):396-8. doi: 10.1007/BF00735926. Cancer Chemother Pharmacol. 1993. PMID: 8339392

8

Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells.

Baker WJ, Wiebe VJ, Koester SK, Emshoff VD, Maenpaa JU, Wurz GT, DeGregorio MW. Baker WJ, et al. Among authors: emshoff vd. Breast Cancer Res Treat. 1992;24(1):43-9. doi: 10.1007/BF01832357. Breast Cancer Res Treat. 1992. PMID: 1463871

9

Toremifene enhances cell cycle block and growth inhibition by vinblastine in multidrug resistant human breast cancer cells.

Baker WJ, Maenpaa JU, Wurz GT, Koester SK, Seymour RC, Emshoff VD, Wiebe VJ, DeGregorio MW. Baker WJ, et al. Among authors: emshoff vd. Oncol Res. 1993;5(6-7):207-12. Oncol Res. 1993. PMID: 8123940

10

Pharmacokinetic analysis of high-dose toremifene in combination with doxorubicin.

Wurz GT, Soc L, Emshoff VD, Cadman TB, DeGregorio MW. Wurz GT, et al. Among authors: emshoff vd. Cancer Chemother Pharmacol. 1998;42(5):363-6. doi: 10.1007/s002800050830. Cancer Chemother Pharmacol. 1998. PMID: 9771949 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters